Victory Capital Management Inc. Has $1.50 Million Position in Elanco Animal Health Incorporated (NYSE:ELAN)

Victory Capital Management Inc. boosted its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 10.2% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 102,414 shares of the company’s stock after purchasing an additional 9,480 shares during the quarter. Victory Capital Management Inc.’s holdings in Elanco Animal Health were worth $1,504,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Magnetar Financial LLC increased its position in Elanco Animal Health by 61.2% during the second quarter. Magnetar Financial LLC now owns 8,336,657 shares of the company’s stock worth $120,298,000 after acquiring an additional 3,164,350 shares during the period. The Manufacturers Life Insurance Company raised its stake in shares of Elanco Animal Health by 11.3% in the second quarter. The Manufacturers Life Insurance Company now owns 5,990,546 shares of the company’s stock valued at $86,444,000 after purchasing an additional 609,194 shares in the last quarter. Canada Pension Plan Investment Board bought a new position in Elanco Animal Health in the second quarter worth $55,599,000. Douglas Lane & Associates LLC boosted its stake in Elanco Animal Health by 1.0% during the third quarter. Douglas Lane & Associates LLC now owns 3,767,784 shares of the company’s stock worth $55,349,000 after buying an additional 37,349 shares in the last quarter. Finally, Brandes Investment Partners LP increased its holdings in Elanco Animal Health by 1.3% in the 2nd quarter. Brandes Investment Partners LP now owns 2,945,967 shares of the company’s stock valued at $42,445,000 after buying an additional 36,944 shares during the period. Institutional investors and hedge funds own 97.48% of the company’s stock.

Elanco Animal Health Trading Up 0.2 %

ELAN stock opened at $13.39 on Tuesday. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. The stock has a market capitalization of $6.62 billion, a price-to-earnings ratio of 33.48, a P/E/G ratio of 1.39 and a beta of 1.41. The business has a fifty day moving average price of $13.68 and a 200 day moving average price of $14.72. Elanco Animal Health Incorporated has a fifty-two week low of $11.40 and a fifty-two week high of $18.80.

Elanco Animal Health (NYSE:ELAN) last announced its earnings results on Thursday, November 7th. The company reported $0.13 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.12 by $0.01. The company had revenue of $1.03 billion for the quarter, compared to analyst estimates of $1.04 billion. Elanco Animal Health had a net margin of 4.60% and a return on equity of 6.78%. Elanco Animal Health’s quarterly revenue was down 3.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.18 earnings per share. Analysts expect that Elanco Animal Health Incorporated will post 0.91 EPS for the current fiscal year.

Analyst Ratings Changes

ELAN has been the topic of several recent research reports. Stifel Nicolaus reiterated a “buy” rating and set a $20.00 target price on shares of Elanco Animal Health in a research report on Thursday, September 19th. Morgan Stanley lowered Elanco Animal Health from an “overweight” rating to an “equal weight” rating and decreased their price target for the company from $17.00 to $15.00 in a research note on Thursday, September 19th. Finally, Barclays increased their price objective on Elanco Animal Health from $19.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday, November 8th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $17.14.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.